Kolexia
Hogan Julien Pédiatrie
Hogan Julien
Pédiatrie
Hôpital Robert-Debré
Paris, France
191 Activités
35 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndrome néphrotique Défaillance rénale chronique Maladies du rein Protéinurie Néphrite Glomérulonéphrite à dépôts d'IgA Insuffisance rénale chronique Glomérulonéphrite Insuffisance rénale

Collaborateurs

Voir plus
Deschenes Georges
Deschenes Georges
Hôpital Robert-Debré, Paris, France
Dossier Claire
Dossier Claire
Hôpital Robert-Debré, Paris, France
Baudouin Veronique
Baudouin Veronique
Hôpital Robert-Debré, Paris, France
Boyer Olivia
Boyer Olivia
Hôpital Necker Enfants Malades, Paris, France

Industries

Voir plus
Novartis
4 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
2 collaboration(s)
Dernière en 2020
Bouchara-Recordati
2 collaboration(s)
Dernière en 2023
retrophin
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
MAJESTY: A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
Essai Clinique (Roche)   21 mars 2024
POSTERITY: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)
Essai Clinique (Roche)   15 mars 2024
ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Essai Clinique (Alnylam)   08 mars 2024
INShore: A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome
Essai Clinique (Roche)   27 février 2024
Reply to Angeletti et al-Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons   21 février 2024
Unrecognized opportunities: The landscape of pediatric kidney-paired donation in the United States.
Pediatric transplantation   07 février 2024
REGENCY: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)
Essai Clinique (Roche)   22 janvier 2024
Steroid-Resistant Nephrotic Syndrome due to NPHS2 Variants Is Not Associated With Posttransplant Recurrence
Kidney international reports   10 janvier 2024
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications: A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Essai Clinique (BMS)   04 janvier 2024
OBIRINS: Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome : a Double-blind Multicenter Randomized Controlled Study
Essai Clinique (Assistance publique – Hôpitaux de Paris)   08 novembre 2023